D-0083-2024 Class II Terminated
FDA drug recall D-0083-2024 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Oct 20, 2023 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is terminated (terminated Jul 25, 2024). Affected quantity: 7392 Bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 8, 2023
- Initiation Date
- Oct 20, 2023
- Termination Date
- Jul 25, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7392 Bottles
Product description
Liothyronine Sodium Tablets, USP, 5 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc.Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191,(U.T. of D & NH), India. NDC 62756-589-88
Reason for recall
Failed Impurities/Degradation Specifications.
Distribution pattern
Nationwide within the United States
Code information
Lot #: DND0058A, Exp. Date 12/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0083-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026